Apollo Pharmacy Blood Glucose Monitoring System APG-01 BT (CVE-2026-50034, CVE-2026-52866)

What Happened

The Apollo Pharmacy Blood Glucose Monitoring System has two security flaws that affect its Bluetooth connection. Anyone using this specific device (Model APG-01 BT) is affected. Because of these flaws, someone nearby could potentially read a user's sensitive health data, like glucose levels, or block the user from connecting to their own device. The manufacturer has not provided a fix, so users should be cautious about using the device's Bluetooth features in public spaces.

Key Takeaways

• The Apollo Pharmacy Blood Glucose Monitoring System APG-01 BT is affected by two vulnerabilities (CVE-2026-50034, CVE-2026-52866).
• An attacker within Bluetooth Low Energy (BLE) range can passively intercept sensitive health data, such as glucose measurements, transmitted in cleartext.
• An attacker within BLE range can monopolize the device's single connection slot, causing a denial-of-service (DoS) condition for legitimate users.
• The vendor has not responded to CISA's coordination requests, meaning no official patch or firmware update is currently available.

Affected Systems

• Apollo Pharmacy Blood Glucose Monitoring System (Model No. APG-01 BT) version 0x0110_v1.1.0

Vulnerabilities (CVEs)

• CVE-2026-50034
• CVE-2026-52866

Attack Chain

An attacker positions themselves within Bluetooth Low Energy (BLE) range of the vulnerable Apollo Pharmacy Blood Glucose Monitoring System. To exploit CVE-2026-50034, the attacker passively sniffs the BLE traffic to intercept cleartext health data, such as glucose measurements. To exploit CVE-2026-52866, the attacker actively connects to the device, monopolizing its single BLE connection slot and preventing the legitimate user or application from accessing the device.

Detection Availability

• YARA Rules: No
• Sigma Rules: No
• Snort/Suricata Rules: No
• KQL Queries: No
• Splunk SPL Queries: No
• EQL Queries: No
• Other Detection Logic: No

No specific detection rules are provided in the advisory.

Detection Engineering Assessment

EDR Visibility: None — EDR agents cannot be installed on embedded medical devices and do not monitor local Bluetooth Low Energy (BLE) traffic. Network Visibility: None — The vulnerabilities are exploited via local BLE connections, which bypass standard IP-based network monitoring and firewalls. Detection Difficulty: Very Hard — Detecting passive BLE sniffing is nearly impossible without specialized physical-layer monitoring, and detecting connection monopolization requires local wireless intrusion detection systems (WIDS) that are rarely deployed in non-enterprise environments.

Required Log Sources

• Wireless Intrusion Detection System (WIDS) logs

Hunting Hypotheses

Control Gaps

• Lack of BLE traffic encryption
• Lack of Wireless Intrusion Detection Systems (WIDS) in typical usage environments

Key Behavioral Indicators

• Inability of legitimate applications to pair with the device
• Anomalous BLE connection durations from unrecognized MAC addresses

False Positive Assessment

• Low

Recommendations

Immediate Mitigation

• Verify against your organization's incident response runbook and team escalation paths before acting.
• Consider disabling Bluetooth functionality on the affected devices if not strictly required for patient care.
• Evaluate whether patients can be transitioned to alternative glucose monitoring systems until a patch is available.

Infrastructure Hardening

• If applicable, implement Wireless Intrusion Detection Systems (WIDS) in clinical environments to monitor for anomalous BLE connections.

User Protection

• Advise users to avoid pairing or using the device's Bluetooth features in public or untrusted physical locations.

Security Awareness

• Educate patients and healthcare providers about the risks of using unpatched, Bluetooth-enabled medical devices in public spaces.

MITRE ATT&CK Mapping

• T1040 - Network Sniffing
• T1498 - Network Denial of Service